Adalimumab biosimilar (DZM Biotech)

阿达木单抗生物类似药（大庆东竺明生物）

Report date: 2022/07/15 15:59:06

Base Information

Drug NameAdalimumab biosimilar (DZM Biotech)
Drug Alias Name阿达木单抗生物仿制药（大庆东竺明生物）Adalimumab biosimilar (DZM Biotech)Human anti-TNFα monoclonal antibody (DZM Biotech)抗TNFα全人源单克隆抗体注射液（大庆东竺明生物）抗TNFα全人源单克隆抗体（大庆东竺明生物）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDzm Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDzm Biotech Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A